The clinical trials of BET inhibitors were performed in patients with hematological malignancies (AML, lymphoma, myeloma, myelofibrosis) and solid tumors (prostate cancer, lung carcinoma, melanoma, breast cancer, sarcoma, NUT midline carcinoma). The gene discussed is DNER; the disease is breast cancer.